MedStar Authors catalog › Details for: High-Sensitivity Troponin I Levels and Coronary Artery Disease Severity, Progression, and Long-Term Outcomes.
Normal view MARC view ISBD view

High-Sensitivity Troponin I Levels and Coronary Artery Disease Severity, Progression, and Long-Term Outcomes.

by Epstein, Stephen E.
Citation: Journal of the American Heart Association. 7(5), 2018 Feb 21.Journal: Journal of the American Heart Association.Published: 2018ISSN: 2047-9980.Full author list: Samman Tahhan A; Sandesara P; Hayek SS; Hammadah M; Alkhoder A; Kelli HM; Topel M; O'Neal WT; Ghasemzadeh N; Ko YA; Gafeer MM; Abdelhadi N; Choudhary F; Patel K; Beshiri A; Murtagh G; Kim J; Wilson P; Shaw L; Vaccarino V; Epstein SE; Sperling L; Quyyumi AA.UI/PMID: 29467150.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Health Research InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: (Click here) Abbreviated citation: J Am Heart Assoc. 7(5), 2018 Feb 21.Abstract: BACKGROUND: The associations between high-sensitivity troponin I (hsTnI) levels and coronary artery disease (CAD) severity and progression remain unclear. We investigated whether there is an association between hsTnI and angiographic severity and progression of CAD and whether the predictive value of hsTnI level for incident cardiovascular outcomes is independent of CAD severity.Abstract: METHODS AND RESULTS: In 3087 patients (aged 63+/-12 years, 64% men) undergoing cardiac catheterization without evidence of acute myocardial infarction, the severity of CAD was calculated by the number of major coronary arteries with >=50% stenosis and the Gensini score. CAD progression was assessed in a subset of 717 patients who had undergone >=2 coronary angiograms >3 months before enrollment. Patients were followed up for incident all-cause mortality and incident cardiovascular events. Of the total population, 11% had normal angiograms, 23% had nonobstructive CAD, 20% had 1-vessel CAD, 20% had 2-vessel CAD, and 26% had 3-vessel CAD. After adjusting for age, sex, race, body mass index, smoking, hypertension, diabetes mellitus history, and renal function, hsTnI levels were independently associated with the severity of CAD measured by the Gensini score (log 2 s=0.31; 95% confidence interval, 0.18-0.44; P<0.001) and with CAD progression (log 2 s=0.36; 95% confidence interval, 0.14-0.58; P=0.001). hsTnI level was also a significant predictor of incident death, cardiovascular death, myocardial infarction, revascularization, and cardiac hospitalizations, independent of the aforementioned covariates and CAD severity.Abstract: CONCLUSIONS: Higher hsTnI levels are associated with the underlying burden of coronary atherosclerosis, more rapid progression of CAD, and higher risk of all-cause mortality and incident cardiovascular events. Whether more aggressive treatment aimed at reducing hsTnI levels can modulate disease progression requires further investigation.Abstract: Copyright (c) 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

Powered by Koha